AEMD

Aethlon Medical, Inc. (AEMD) - 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended December 31, 2025, and the nine months ended on that date. Aethlon Medical is a clinical-stage medical therapeutic company developing the Hemopurifier® (HP), a device designated as a "Breakthrough Device" by the FDA for treating advanced cancer and life-threatening viral infections. The company operates as a single segment and is currently focused on a safety, feasibility, and dose-finding oncology trial in Australia.

Key Financial Metrics

Note: The company has no commercial revenue. Operating expenses include Research & Development (R&D) costs embedded within payroll, professional fees, and general and administrative (G&A) lines.

Material Changes vs. Prior Period

• Expense Reduction (9 Months): Total operating expenses decreased by approximately $1.97 million (26.9%) compared to the nine months ended December 31, 2024. This was driven by a $1.085 million decrease in payroll (due to prior period severance charges and lower headcount) and a $527,000 decrease in G&A expenses.
• R&D Tax Incentive: The company recognized an Australian R&D tax incentive of approximately $218,000, which reduced reported R&D expenses for the nine-month period.
• Strategic Pivot: The company cancelled a planned clinical trial in India to conserve resources and focus on the Australian oncology trial, contributing to lower clinical trial expenses.
• Capital Raise: Net cash provided by financing activities increased to $6.72 million for the nine months ended Dec 31, 2025, compared to $5.37 million in the prior year period, primarily due to a PIPE offering and warrant exercises.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. Existing cash as of December 31, 2025, is not expected to fund operations for at least twelve months. Additional capital is required to sustain clinical trials and operations.
• Clinical Progress: The Australian oncology trial completed Cohort 1 (3 participants) with no safety concerns. Cohort 2 enrollment has begun, with two participants treated as of the filing date. The trial aims to enroll 9-18 patients total.
• Financing Activity: In December 2025, the company closed a PIPE offering raising approximately $3.3 million (gross) via pre-funded warrants and common warrants. In January 2026, a registration statement for the resale of these shares was declared effective, and pre-funded warrants were amended to be immediately exercisable.
• Regulatory Risks: The company faces risks related to a partial U.S. government shutdown (beginning Jan 31, 2026), which could delay FDA reviews. Additionally, the company is awaiting FDA approval for a manufacturing supplement to qualify a key component supplier.
• Stock Structure: The company implemented a 1-for-10 reverse stock split in October 2025 and a 1-for-8 reverse stock split in June 2025 to maintain Nasdaq listing compliance. All historical share data in the filing has been retroactively adjusted.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" disclosure regarding the 12-month liquidity horizon.
• Warrant Exercisability: Confirm the status of stockholder approval required for the exercise of the 1.4 million+ warrants issued in the December 2025 PIPE offering.
• Clinical Trial Enrollment: Monitor the pace of patient enrollment in the Australian Cohort 2 trial to ensure it meets the projected timeline.
• Manufacturing Approval: Track the status of the FDA IDE supplement approval required for the new component supplier to ensure uninterrupted trial supply.
• Government Shutdown Impact: Assess the potential delay to regulatory filings caused by the U.S. government shutdown noted in the risk factors.